GlassScriptPhysician profile
Jennifer R Lewis
NPI 1417300419
$2,864.74
in general payments reported to CMS, 2019-2025
28 companies · $703 in 2025
The $703 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $479 · 2023: $804 · 2024: $610 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.42 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $511.20 | 2021-2025 | Lynparza, Imfinzi, Enhertu |
| Novocure INC. | $356.71 | 2022-2024 | Optune |
| Seagen INC. | $268.60 | 2021-2023 | |
| Abbvie INC. | $250.04 | 2025 | |
| Daiichi Sankyo INC. | $216.83 | 2024-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $166.31 | 2023-2025 | Libtayo |
| Janssen Biotech, INC. | $163.67 | 2023-2025 | Carvykti, Darzalex, Tecvayli |
| Exelixis INC. | $125.00 | 2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $108.41 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.14 | 2022 | |
| Merck Sharp & Dohme LLC | $74.17 | 2023 | Keytruda, Welireg, Reblozyl |
| Pfizer INC. | $53.76 | 2024 | |
| Novartis Pharmaceuticals Corporation | $50.44 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $39.23 | 2023-2025 | Ultomiris |
| Eisai INC. | $38.70 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $36.63 | 2023-2024 | Phesgo, Gazyva, Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $33.89 | 2023 | |
| Emd Serono, INC. | $33.13 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.99 | 2021-2024 | Cobenfy |
| Genzyme Corporation | $30.69 | 2023-2024 | |
| Celgene Corporation | $30.15 | 2023 | Reblozyl |
| Lilly USA, LLC | $29.67 | 2023-2024 | Verzenio, Jaypirca |
| Incyte Corporation | $27.91 | 2023 | Jakafi, Monjuvi |
| Acrotech Biopharma INC. | $20.25 | 2024 | Beleodaq |
| Karyopharm Therapeutics INC. | $18.84 | 2021 | |
| Mirati Therapeutics, INC. | $18.09 | 2023 | Krazati |
| Amgen INC. | $16.90 | 2021 | |
| Aveo Pharmaceuticals, INC. | $15.39 | 2023 | Fotivda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.